PubRank

Claus Christiansen

Author PubWeight™ 231.64‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006 19.03
2 Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009 13.57
3 A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007 13.28
4 Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007 12.65
5 Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008 6.35
6 Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 2007 5.88
7 Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 2012 5.48
8 Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 2012 4.81
9 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004 4.04
10 The effects of tibolone in older postmenopausal women. N Engl J Med 2008 3.96
11 New sequence variants associated with bone mineral density. Nat Genet 2008 3.43
12 Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation 2003 3.37
13 Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006 2.82
14 Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche. Nat Genet 2009 2.58
15 Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature 2013 2.55
16 Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005 2.49
17 Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation 2005 2.30
18 The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum 2007 2.22
19 Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet 2011 2.21
20 Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 2012 1.92
21 Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 2007 1.82
22 Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008 1.79
23 Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 2005 1.77
24 Segmenting articular cartilage automatically using a voxel classification approach. IEEE Trans Med Imaging 2007 1.73
25 Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 2009 1.73
26 Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 2004 1.66
27 Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol 2003 1.64
28 Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr Med Res Opin 2012 1.64
29 A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res 2014 1.56
30 Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003 1.52
31 An update on the antiestrogenic effect of smoking: a literature review with implications for researchers and practitioners. Menopause 2004 1.49
32 Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 2008 1.43
33 The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacol Res 2008 1.38
34 Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009 1.34
35 Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008 1.32
36 Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011 1.32
37 Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther 2009 1.30
38 Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol 2012 1.30
39 Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 2005 1.26
40 Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities. Arthritis Res Ther 2011 1.22
41 Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 2005 1.17
42 Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum 2007 1.17
43 Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003 1.16
44 Associations between aortic calcification and components of body composition in elderly men. Obesity (Silver Spring) 2006 1.11
45 Automatic segmentation of the articular cartilage in knee MRI using a hierarchical multi-class classification scheme. Med Image Comput Comput Assist Interv 2005 1.10
46 The implications of body fat mass and fat distribution for cognitive function in elderly women. Obes Res 2004 1.09
47 Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int 2010 1.09
48 Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 2006 1.08
49 Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 2010 1.08
50 Novel associations between bioavailable estradiol and adipokines in elderly women with different phenotypes of obesity: implications for atherogenesis. Circulation 2004 1.07
51 The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: results from the Prospective Epidemiological Risk Factors study. Osteoporos Int 2005 1.06
52 Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. Arthritis Rheum 2004 1.05
53 Central and peripheral fat mass have contrasting effect on the progression of aortic calcification in postmenopausal women. Eur Heart J 2003 1.02
54 Leptin receptor genotype at Gln223Arg is associated with body composition, BMD, and vertebral fracture in postmenopausal Danish women. J Bone Miner Res 2007 1.02
55 Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Ther 2013 1.02
56 Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004 1.01
57 Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004 1.01
58 Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone 2006 1.01
59 Automated detection of hypoglycemia-induced EEG changes recorded by subcutaneous electrodes in subjects with type 1 diabetes--the brain as a biosensor. Diabetes Res Clin Pract 2010 0.99
60 Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005 0.99
61 Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 2008 0.98
62 ACDC/adiponectin and PPAR-gamma gene polymorphisms: implications for features of obesity. Obes Res 2005 0.98
63 Variations in percentage of body fat within different BMI groups in young, middle-aged and old women. Clin Physiol Funct Imaging 2003 0.97
64 Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 2004 0.96
65 Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 2007 0.96
66 Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 2004 0.94
67 Appendicular lean tissue mass and the prevalence of sarcopenia among healthy women. Metabolism 2002 0.94
68 Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am J Transl Res 2012 0.93
69 Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann N Y Acad Sci 2007 0.93
70 The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res 2013 0.93
71 Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline. J Clin Rheumatol 2014 0.91
72 Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis--a serological evaluation. Liver Int 2012 0.90
73 Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. J Clin Endocrinol Metab 2004 0.90
74 Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression. Arthritis Rheum 2013 0.89
75 Genome-wide association study for radiographic vertebral fractures: a potential role for the 16q24 BMD locus. Bone 2014 0.88
76 Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression? Drugs 2006 0.88
77 Musculoskeletal ageing and primary prevention. Best Pract Res Clin Obstet Gynaecol 2013 0.88
78 Role of hormones in cartilage and joint metabolism: understanding an unhealthy metabolic phenotype in osteoarthritis. Menopause 2013 0.88
79 Application of biochemical markers in development of drugs for treatment of osteoarthritis. Biomarkers 2010 0.88
80 Estrogen receptor alpha and beta polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy? Menopause 2006 0.88
81 Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer. Cancer Med 2014 0.88
82 The aging male: testosterone deficiency and testosterone replacement. An up-date. Atherosclerosis 2004 0.87
83 Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers? Cancer Metastasis Rev 2006 0.87
84 Oral salmon calcitonin--pharmacology in osteoporosis. Expert Opin Biol Ther 2010 0.87
85 Accuracy evaluation of automatic quantification of the articular cartilage surface curvature from MRI. Acad Radiol 2007 0.87
86 Visceral fat is more important than peripheral fat for endometrial thickness and bone mass in healthy postmenopausal women. Am J Obstet Gynecol 2003 0.87
87 Estrogen receptor alpha and risk for cognitive impairment in postmenopausal women. Psychiatr Genet 2006 0.86
88 A MMP derived versican neo-epitope is elevated in plasma from patients with atherosclerotic heart disease. Int J Clin Exp Med 2013 0.86
89 Quantification of "end products" of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways -- implications for modern clinical chemistry. Biomarkers 2013 0.86
90 RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res 2014 0.85
91 Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 2004 0.85
92 Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone 2006 0.85
93 Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev 2011 0.85
94 Rheumatoid arthritis: a case for personalized health care? Arthritis Care Res (Hoboken) 2014 0.85
95 Automatic quantification of local and global articular cartilage surface curvature: biomarkers for osteoarthritis? Magn Reson Med 2008 0.85
96 An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 2004 0.85
97 Lack of association of the serotonin transporter gene promoter region polymorphism, 5-HTTLPR, including rs25531 with cigarette smoking and alcohol consumption. Am J Med Genet B Neuropsychiatr Genet 2009 0.84
98 Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. Curr Med Res Opin 2008 0.83
99 Association of a dopamine beta-hydroxylase gene variant with depression in elderly women possibly reflecting noradrenergic dysfunction. J Affect Disord 2007 0.83
100 Can the obesity paradox be explained by the protective effects of peripheral adiposity? Arch Intern Med 2005 0.83
101 The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy. Bone 2004 0.83
102 Evaluation of cartilage damage by measuring collagen degradation products in joint extracts in a traumatic model of osteoarthritis. Biomarkers 2008 0.82
103 The effect of hormone replacement therapy on appendicular lean tissue mass in early postmenopausal women. Menopause 2002 0.82
104 Biochemical markers of joint tissue turnover. Assay Drug Dev Technol 2010 0.82
105 Pulsed estrogen therapy improves postmenopausal quality of life: a 2-year placebo-controlled study. Maturitas 2006 0.82
106 Automatic quantification of tibio-femoral contact area and congruity. IEEE Trans Med Imaging 2012 0.81
107 Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin. BMC Clin Pharmacol 2008 0.81
108 Clinical evaluation of a matrix metalloproteinase-12 cleaved fragment of titin as a cardiovascular serological biomarker. J Transl Med 2012 0.81
109 Human macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processes. BMC Cardiovasc Disord 2010 0.81
110 Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS One 2013 0.81
111 Low-dose transdermal estradiol induces breast density and heterogeneity changes comparable to those of raloxifene. Menopause 2009 0.80
112 Osteoarthritic cartilage is more homogeneous than healthy cartilage: identification of a superior region of interest colocalized with a major risk factor for osteoarthritis. Acad Radiol 2007 0.80
113 Selective monitoring of vitamin D2 and D3 supplementation with a highly specific 25-hydroxyvitamin D3 immunoassay with negligible cross-reactivity to 25-hydroxyvitamin D2. Clin Chim Acta 2009 0.79
114 Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br J Clin Pharmacol 2009 0.79
115 An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function. PLoS One 2013 0.79
116 Proteasome inhibitors stimulate both bone formation and hair growth by similar mechanisms. Ann N Y Acad Sci 2007 0.79
117 Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy. Eur J Clin Pharmacol 2009 0.79
118 Comparison of quantitative ultrasound of the phalanges with conventional bone densitometry in healthy postmenopausal women. Osteoporos Int 2005 0.78
119 Distribution, size, and shape of abdominal aortic calcified deposits and their relationship to mortality in postmenopausal women. Int J Biomed Imaging 2012 0.78
120 Distribution, size, shape, growth potential and extent of abdominal aortic calcified deposits predict mortality in postmenopausal women. BMC Cardiovasc Disord 2010 0.78
121 Breast density changes associated with postmenopausal hormone therapy: post hoc radiologist- and computer-based analyses. Menopause 2010 0.78
122 Lessons learned from the clinical development of oral peptides. Br J Clin Pharmacol 2015 0.78
123 Long-term prevention with hormone-replacement therapy after the menopause: which women should be targeted? Womens Health (Lond Engl) 2009 0.77
124 Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioning. Drug Discov Today 2011 0.77
125 Serum placental protein 14: a novel marker of selective oestrogen receptor modulator action on the postmenopausal endometrium. Biomarkers 2002 0.77
126 Lack of difference among progestins on the anti-atherogenic effect of ethinyl estradiol: a rabbit study. Hum Reprod 2003 0.77
127 A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin. J Clin Pharmacol 2009 0.77
128 Cognitive performance in elderly women: significance of the 19bp insertion/deletion polymorphism in the 5' flank of the dopamine beta-hydroxylase gene, educational level, body fat measures, serum triglyceride, alcohol consumption and age. Int J Geriatr Psychiatry 2007 0.77
129 Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs. A review. Am J Obstet Gynecol 2002 0.77
130 Quantifying calcification in the lumbar aorta on X-ray images. Med Image Comput Comput Assist Interv 2007 0.77
131 Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats. Menopause 2013 0.76
132 Obesity susceptibility CART gene polymorphism contributes to bone remodeling in postmenopausal women. Osteoporos Int 2006 0.76
133 Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial. Menopause 2009 0.76
134 What can be learned from the levormeloxifene experience? Acta Obstet Gynecol Scand 2006 0.76
135 Menopause, estrogens and frailty. Gynecol Endocrinol 2013 0.76
136 A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Eur J Pharmacol 2009 0.76
137 Associated response in bone and lipids during hormone replacement therapy. Maturitas 2004 0.76
138 Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments. Breast Cancer Res 2003 0.76
139 Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause 2004 0.75
140 Metabolic syndrome and subsequent risk of type 2 diabetes and cardiovascular disease in elderly women: Challenging the current definition. Medicine (Baltimore) 2016 0.75
141 Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats. Menopause 2013 0.75
142 Does increased local bone resorption secondary to breast and prostate cancer result in increased cartilage degradation? BMC Cancer 2008 0.75
143 The clinical potential of estrogen for the prevention of osteoarthritis: what is known and what needs to be done? Womens Health (Lond Engl) 2005 0.75
144 Can confounding with fat-derived endogenous free estradiol explain the inverse correlation of bone mineral density with adiponectin? Bone 2004 0.75
145 Abdominal aortic calcification quantified by the Morphological Atherosclerotic Calcification Distribution (MACD) index is associated with features of the metabolic syndrome. BMC Cardiovasc Disord 2011 0.75
146 Late-Life Risk Factors for All-Cause Dementia and Differential Dementia Diagnoses in Women: A Prospective Cohort Study. Medicine (Baltimore) 2016 0.75
147 Long-term risk of malignant neoplasm associated with gestational glucose intolerance. Cancer 2004 0.75
148 Recommendations on the management of fragility fracture risk in women younger than 70 years. Gynecol Endocrinol 2012 0.75
149 Cognitive impairment in elderly women: the relative importance of selected genes, lifestyle factors, and comorbidities. Neuropsychiatr Dis Treat 2006 0.75
150 Herbert Andre Fleisch, MD : 22 July 1933-15 May 2007. Osteoporos Int 2007 0.75
151 Corrigendum: Whole-genome sequencing identifies rare genotypes in COMP and CHADL associated with high risk of hip osteoarthritis. Nat Genet 2017 0.75
152 Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen. Hum Reprod 2009 0.75
153 Molecular serum and urine marker repertoire supporting clinical research on joint diseases. Best Pract Res Clin Rheumatol 2011 0.75
154 Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study. Osteoporos Int 2003 0.75